Galien Forum & Prix Galien

Report October 26, 2017 New York City Galien Forum & Prix Galien USA 2017 Cures will emerge when physician-scientists partner with pharmaceutical companies to expose and target the Achilles heel of disease. The Prix Galien rewards those at the forefront of this battle. Michael Brown, Nobel Laureate & Professor, The sixth annual Galien Forum took place on According to Steven Pearson, President of University of Texas, Southwestern Medical Center October 26, 2017 at the Alexandria Center for the Institute for Clinical and Economic Review, Life Science in New York City, followed by the “the stimulating ferment created by bringing ~ eleventh annual Prix Galien USA Awards together the academic superstars and the The Galien Foundation Ceremony in the iconic blue-whale room of the innovative companies in attendance was a real amplifies the connection American Museum of Natural History. reminder to me of how exciting, vital, and between academia and deeply honorable the drug discovery process industry so that innovation Forum participants tackled the most pressing is. It was particularly meaningful for me to help can fulfill its potential and issues in healthcare and R&D today, and the improve the human bring the conversation about drug pricing into ceremony recognized and honored the figurative this arena.” Panelists also included Peter condition. – and occasionally literal – blood, sweat, and Bach, Director for the Center for Health Policy Olivia Flatto, President, tears that go into creating innovation to improve & Outcomes at Memorial Sloan Kettering Pershing Square Foundation the human condition. Both events welcomed a Cancer Center; Steve Miller, Senior Vice ~ star-studded list of attendees and speakers President & Chief medical Officer at Express The best of the best come to comprised of Nobel Laureates; biopharma- Scripts; Leonard Schleifer, Founder, the Galien Forum for cutting- ceutical, biotech and medical device CEOs; President, and CEO of Regeneron edge conversation about life leading researchers, scientists and Pharmaceuticals; and Stephen Ubl, President sciences R&D – innovation academicians; policymakers; and civil society and CEO of PhRMA, who called for public for human health the leaders. policies that “reward the two essential technology that supports it, elements of every life-saving treatment – and the issues that Tackling Drug Pricing and Access financial investment and time.” researchers, patients, During the Galien Forum’s keynote panel, policymakers, and life industry leaders discussed drug pricing and State-of-the-Art in Inflammation science companies are Disorders access through the lens of the Trump wrestling with. Administration. Panelists addressed gaps in the The kick-off plenary panel took a deep dive Steve Rosenberg, Senior current policy and regulatory armamentarium Vice President & General into inflammatory skin diseases and their Manager, Oracle Health that limit patient access to new medicines; mechanistic interconnections to other Sciences discussed new framework tools and inflammation disorders. Chaired by Michael ~ methodologies to evaluate the value of new Dolsten, President of Worldwide R&D for medicines against the existing standard of care; The Galien Forum and Prix Pfizer, the discussion explored how recent highlighted best industry practices to improve Galien USA events are the innovation can be applied across the Davos of life science right access and pricing; and considered new spectrum. here in Manhattan. partnering arrangements with other stakeholders. Cynthia Tsai, CEO, Healthquest 1 The successful development About Us of a new drug isn’t just a The Prix Galien was founded in blessing to mankind; it is a France in 1970 by pharmacist demonstration that some- Roland Mehl in honor of Galen—the father of medical times, by dint of creativity, science and modern perseverance, and a bit of pharmacology. It recognizes luck, medical science can look the efforts of scientists, researchers, and companies a disease straight in the eye committed to advancing and say: Not this time. medical innovation with the power to change the human Laurie Glimcher, President & CEO, Dana condition. Farber Cancer Institute; Professor, Harvard Medical School Regarded as the Nobel Prize equivalent of biopharma- ceutical and medical technology research, the Prix With these new treatments and Founder at Alexandria Real “Why invest now? Because we Galien has been introduced come new challenges rooted in Estate Equities/Alexandria have increased our across Europe and North regulatory pathways and risk Venture Investments and Co- understanding of the biology of America and is now the most tolerance, payer acceptance, Founder of the Alexandria the blood/brain barrier. Recent prestigious award of its kind in and provider uptake, as well as Summit, and Lynn Zydowsky, advances in elucidating the 14 countries. In addition, an infrastructure needed to President and Co-Founder of the genetic associations also make International Prix Galien award leverage precision medicine Alexandria Summit and Chief this a very exciting time. is given every two years, and biomarkers, to advance Science Advisor to the CEO of Critical to success are selected from previous winners better big data approaches to Alexandria Real Estate validated biomarkers, across the globe. immuno-profiling. Addressing Equities/Alexandria Venture identifying the right patients for Investments. treatment, and proper timing of The Prix Galien USA launched these challenges requires significant time and human treatment intervention.” Jean in 2007 in New York City, Speakers examined such resources. Francois Formela, Partner at followed by the introduction of questions as what incentives are the Galien Forum. These Atlas Ventures, reminded “Health is one of the hardest – necessary to attract venture events represent a peer-to- participants to approach capital support at the key early peer exchange with a public and most important – opportunity systematically: “It purpose. Together, they businesses of all,” noted stages of product development is imperative to consider the feature unique opportunities to George Yancopoulos, and what factors these investors science, tractability of the connect with a diverse range President and Chief Scientific see as most important to target, and unmet need.” of people, organizations, and Officer of Regeneron. “We remaining engaged as funders interests, from professional must realize, as a society, that right through to receipt of a Remaining Challenges in and scientific groups, science is a long-term marketing authorization. José Cardiovascular Disease academia and governments to investment and that the Baselga, Chief Medical Officer Nobel Laureate Bengt patient associations, non-profit timeframes are very long.” for Memorial Sloan Kettering Samuelsson, renowned organizations, and the media. Panelists also included Jim Cancer Center, lauded the biochemist, former President of Kreuger from the Laboratory power of technology in making the Karolinska Institute, and The Galien Foundation’s for Investigative Dermatology such investments go farther, mandate is to foster, former Chairman of the Nobel at Rockefeller University, and faster, and ideally one day recognize, and reward Foundation, chaired a session Dan Littman, Howard Hughes helping patients to know if the excellence in scientific on atrial fibrillation, which Institute Investigator. cancer is gone for good. “New innovation to improve the state focused on novel possibilities technology,” he said, “gives us of human health. As such, a to improve quality of life and Investing in Early-Stage hope.” key pillar of the Galien process longevity in patients with the Research and Unmet is to provide communication Medical Needs most common abnormal and collaboration across Taking Alzheimer’s disease (the th cardiac rhythm. Speakers government, industry, and Addressing the challenges of 6 leading cause of death in the included Carina Blomstrӧm- academia. To that end, the investment issues was a panel United States) as a case study, Lundqvist, Professor of Galien process aligns interests on early-stage life science Ryan Watts, CEO of Denali Cardiology at Uppsala to clear direct pathways for venture capital, co-chaired by Therapeutics, sees hope and University; John Camm, productive partnerships that Joel Marcus, Chairman, CEO opportunity. steer key players across sectors toward game-changing innovation. 2 Professor of Clinical Cardiology the standard of care for and Alfred Sandrock, This is unacceptable,” said Mark at St. George’s, University of patients – improvements that Executive Vice President and Feinberg, CEO of IAVI, “Ebola London; Jӧrg Kreuzer, helped drug researchers Chief Medical Officer at highlights models for vaccine Therapeutic Area Head at achieve greater focus in their Biogen. development and public-private Boehringer Ingelheim; Vivek work in the lab. Daryl De Vivo, partnerships that need to be reimagined.” Reddy, Professor of Cardiac Sidney Carter Professor of What’s Next in Vaccine Electrophysiology at Mt. Sinai’s Neurology and Pediatrics at Innovation? Traditional vaccines are time Icahn School of Medicine; and Columbia University Medical consuming and relatively difficult Lars Ryden, Senior Professor of Center, provided an in-depth Julie Gerberding, former to produce. Speakers explored Cardiology at the Karolinska description of the pain and Director of the U.S. Centers for new approaches like DNA-based Institute. suffering associated with the Disease Control and current

Load more